Table 1. Demographics, clinical-pathological and treatment features.
| Characteristics | n | % | |
|---|---|---|---|
| Sex | Male Female |
48 45 |
51.6 48.4 |
| Age | Median, years Interquartile Range, years |
64 23 |
|
| Eastern Cooperative Oncology Group (ECOG) performance status | 0 1 2 3 Missing |
21 5 1 1 65 |
22.6 5.4 1.1 1.1 65.9 |
| Primary site | Parotid gland Submandibular gland Sublingual gland |
71 21 1 |
76.3 22.6 1.1 |
| Histological type | Salivary duct carcinoma Adenoid cystic carcinoma Mucoepidermoid carcinoma Myoepithelial carcinoma Acinic cell carcinoma Carcinoma ex pleomorphic adenoma Squamous cell carcinoma Oncocytic carcinoma Basal cell adenocarcinoma Adenocarcinoma, not otherwise specified Small cell carcinoma Carcinosarcoma Low-grade cribriform cystadenocarcinoma Solitary fibrous tumour |
20 15 13 11 9 6 6 3 3 3 1 1 1 1 |
21.5 16.1 14.0 11.8 9.7 6.5 6.5 3.2 3.2 3.2 1.1 1.1 1.1 1.1 |
| Stage T | pT1 pT2 pT3 pT4 Missing |
26 27 22 12 6 |
28.0 29.0 23.7 12.9 6.5 |
| Stage N | pN0 pN1 pN2 pN3 pNx Missing |
41 6 8 3 29 6 |
44.1 6.5 8.6 3.2 31.2 6.5 |
| Stage M | cM0 cM1 Missing |
82 8 3 |
88.2 8.6 3.2 |
| Grade | High Intermediate Low Missing |
23 8 17 45 |
24.7 8.6 18.3 48.4 |
| Lymphovascular invasion | Yes No Missing |
21 48 24 |
22.6 51.6 25.8 |
| Perineural invasion | Yes No Missing |
35 37 21 |
37.6 39.8 22.6 |
| Carcinoma ex pleomorphic | Yes No Missing |
6 55 32 |
6.5 59.1 34.4 |
| Extracapsular spread | Yes No Missing |
9 52 32 |
9.7 55.9 34.4 |
| Facial nerve sacrifice | Yes No Missing |
17 45 9 |
23.9 63.4 12.7 |
| ERBB2 status | Positive Negative Missing |
2 4 87 |
2.2 4.3 93.5 |
| Androgen receptor status | Positive Negative Missing |
6 5 82 |
6.5 5.4 88.2 |
| Local treatment | Surgery Adjuvant radiotherapy Adjuvant chemoradiotherapy |
93 66 3 |
100 71 3.2 |
| Systemic treatment | Adjuvant chemotherapy Palliative chemotherapy |
1 9 |
1.1 9.7 |